期刊文献+

临床药师参与救治多脏器功能损害并巨细胞病毒感染患者的实践 被引量:2

Practice of Clinical Pharmacists Participating in the Treatment of Multi-organ Injury Complicating with Cytomegalovirus Infection
原文传递
导出
摘要 目的:探讨临床药师在参与救治多脏器功能损害并巨细胞病毒感染患者中的作用。方法:运用药学专业知识结合患者的实际病情,从药物的药效学、药动学和药品不良反应等方面入手,配合医师选择有效、恰当的治疗药物(喜炎平注射液),将给药间隔由qd调整为q12h,为患者A停用引发皮疹的肝舒宁注射液,为有肝肾功能损害的患者B选择泮托拉唑注射液。结果:通过临床药师和临床医师的合作救治,挽救了重症患者的生命,患者康复出院。结论:成年患者在获巨细胞病毒感染后使用喜炎平注射液可获得满意的疗效,但由于病例数少,还需临床进一步观察。 OBJECTIVE: To discuss the role of clinical pharmacists participating in the treatment of multi-organ injury compli- cating with cytomegalovims infection. METHODS: Using the knowledge of pharmacy and considering about the situation of pa- tients, clinical pharmacists helped the doctor to choose effective and appropriate drug as Xiyanping injection, adjust dosing interval of once a day to every 12 h from pharmacodynamics, phannacokinetics, adverse drug reactions and so on. patient A stopped taking Ganchuning injection which resulted in erythay, and patient B with liver and kindney function damage chose pamtoprazole injection. RESULTS: Severe patients were cured and discharged from the hospital by the cooperation of clinic pharmacist and doctor. CONCLU- SIONS: Xiyanping injection in the treatment of cytomegalovirus infection in adult patients shows satisfactory efficacy, which is still further observed in the clinic due to small number of cases.
出处 《中国药房》 CAS CSCD 2014年第18期1716-1719,共4页 China Pharmacy
关键词 巨细胞病毒感染 多脏器功能损害 临床药师 Cytomegalovirus infection Multi-organ injury Clinical pharmacist
  • 引文网络
  • 相关文献

参考文献23

二级参考文献125

共引文献1067

同被引文献43

  • 1赵霞,汪受传,李德.基于德尔菲(Delphi)法的中医药治疗小儿病毒性肺炎疗效评价方法专家问卷调查分析[J].中华中医药杂志,2007,22(5):281-284. 被引量:22
  • 2Sedlak RH,Castor J,Susan M,et al.Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples[J].J Clin Microbiol,2013,51(7):2 354.
  • 3Fischer L,Laib SK,Jahn G,et al.Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation[J].Antiviral Res,2013,100(3):575.
  • 4Eid AJ,Razonable RR.New developments in the management of cytomegalovirus infection after solid organ transplantation[J].Drugs,2010,70(8):965.
  • 5Gill RB,James SH,Prichard MN.Human cytomegalovirus UL97 kinase alters the accumulation of CDK1[J].JGen Virol,2012,93(8):1 743.
  • 6Drew WL,Miner RC,Marousek GI,et al.Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir,cidofovir or foscarnet[J].J Clin Virol,2006,37(2):124.
  • 7Wang LH,Peck RW,Yin Y,et al.Phase I safety and pharmacokinetic trials of 1263W94,a novel oral anti-human cytomegalovirus agent,in healthy and human immunodeficiency virus-infected subjects[J].Antimicrob Agents Chemother,2003,47(4):1 334.
  • 8Marty FM,Ljungman P,Papanicolaou GA,et al.Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants:a phase 3,double-blind,placebo-controlled,randomised trial[J].Lancet Infect Dis,2011,11(4):284.
  • 9Marty FM,Boeckh M.Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed[J].Curr Opin Virol,2011,1(6):555.
  • 10Winston DJ,Saliba F,Blumberg E,et al.Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients:a randomized,double-blind,multicenter controlled trial[J].Am J Transplant,2012,12(11):3 021.

引证文献2

二级引证文献8

;
使用帮助 返回顶部